Sresan Pharma Owner Arrested Over Cough Syrup Deaths

In an unexpected development, S. Ranganathan, owner of Sresan Pharma, has been arrested in Tamil Nadu. This was after the Coldrif cough syrup produced by the company was linked to the deaths of 20 children in Madhya Pradesh. He was arrested after several days of investigation into the fatal contamination. It has led to public outrage and led to renewed scrutiny of drug regulations in India.

Summary of Arrest and Inquiry

Ajay Pandey, Superintendant of Police (SP) in Chhindwara, stated that Ranganathan was taken into custody. He will next be presented before a court in Chennai. After that, be remanded to Chhindwara, Madhya Pradesh.

The problem began shortly after there were reports of fatalities with children across different places of residence. Those children had escaped with an acute kidney injury. Of the 20 children who died, 17 were from Chhindwara, 2 were from Betul, and 1 was from Pandhurna. According to Rajendra Shukla, the Health Minister of Madhya Pradesh, five children are currently in a serious state.

The testers found that the Coldrif Syrup contained diethylene glycol. It is a highly toxic substance that is commonly used as an industrial solvent, in almost 500 times the allowable amount.

Harmful Components and Regulatory Incompetence

Tamil Nadu’s State Drug Control Department revealed that tests indicated the syrup contained 48.6% diethylene glycol. The toxic substance, if ingested, can cause acute kidney failure and damage multiple organs, especially in children.

According to Tamil Nadu’s Health and Family Welfare Minister, Ma Subramanian, the government has issued two notices to Sresan Pharma. It will be inquiring as to why criminal action should not be initiated. He stated that legal action is underway against the manufacturer of the tainted cough syrup.

The government records show that the Coldrif Syrup was marketed only in their local area. Nevertheless, the national damages exposed serious weaknesses in both quality assurance and distribution management.

Government Action in Madhya Pradesh

The Madhya Pradesh government responded to the incident with immediate government action. The government reassigned or suspended two drug inspectors, a FDA deputy director, and a state drug controller. The action is part of a wider response designed to know how the contaminated cough syrup reached children despite current safety mechanisms.

The incident has highlighted significant failures in drug testing and approval processes. It prompted state and federal agencies to increase their tracking of drug manufacture companies.

Maharashtra FDA Begins Inspections Statewide

The incident has also triggered a response in Maharashtra. The Food and Drug Administration (FDA) ordered immediate inspections of all liquid oral products—including syrups—sold in hospitals and pharmacies.

According to the circular noted by PTI, the FDA has asked all joint commissioners and drug inspectors to prepare detailed lists of manufacturers in their location. Samples will be collected from public and private hospitals, distributors, and sellers to be tested as a priority.

The agency pointed out that the impact is designed to help ensure there are not unsafe medications on the market and to ensure manufacturers maintain quality and safety.

National Issue and Impact on the Sector

This event is one of many incidents related to safe pharmaceuticals in India attracted global attention, worst of all, is a series of diethylene glycol poisoning experiences in other parts of the world in the past nearly always involving substandard or counterfeit drugs.

Public health professionals have emphasized these events are a wake-up call for stronger drug regulations, accountability for routine inspections, and stronger penalties for non-compliance.

The investigation into Sresan Pharma is ongoing and officials are attempting to trace Coldrif Syrup back to its ultimate source in order to avert any future deaths. The event is a stark reminder there are very human consequences for negligence in the pharma space.

For more health news, as well as updates related to this story, please follow the most recent updates and announcements made by the government.